| Literature DB >> 30867776 |
Guan Wang1, Jie Liu1, Jinxia Gao1, Xin Zheng2.
Abstract
Effects of sevoflurane and propofol anesthesia on pulmonary function, matrix metalloproteinase-9 (MMP-9) and postoperative cognition were compared in patients undergoing simple resection of lower lobe of left lung. Retrospective method was used to analyze 58 cases of lung cancer patients treated by simple resection of lower lobe of left lung in the Second Hospital of Dalian Medical University from October 2016 to October 2017, and they were divided into two groups: Sevoflurane group (n=32) with sevoflurane anesthesia and propofol group (n=26) with propofol anesthesia. In the present study, the moment before induction of anesthesia (T1), before the start of one-lung ventilation (T2), before the end of one-lung ventilation (T3), after closed chest surgery (T4), 24 h after surgery (T5), calculate alveolar-arterial oxygen difference (A-aDO2), respiratory index (RI) and intrapulmonary shunt ratio (Qs/Qt), were compared between the two groups. The serum MMP-9 concentration at T1, T4 and T5 were detected by enzyme linked immunosorbent assay. The cognitive function of two groups was assessed by Mini-Mental State Examination (MMSE) 1 day before surgery and 1 and 10 days after surgery. The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group (P<0.05). The RI level at T3, T4, the Qs/Qt and the MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group (P<0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery (P<0.05). Propofol has little effect on pulmonary function and can decrease inflammatory factor MMP-9. Both sevoflurane and propofol have an effect on cognitive function after lung cancer resection, but propofol can reduce cognitive impairment in patients with lung cancer.Entities:
Keywords: MMP-9; cognitive function; lung cancer resection; propofol; pulmonary function; sevoflurane
Year: 2019 PMID: 30867776 PMCID: PMC6396185 DOI: 10.3892/ol.2019.9993
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Basic information [n (%)].
| Groups | ||||
|---|---|---|---|---|
| Factors | Sevoflurane (n=32) | Propofol (n=26) | t/χ2 | P-value |
| Age (years) | 0.288 | 0.782 | ||
| <52 | 12 (37.50) | 8 (30.77) | ||
| ≥52 | 20 (62.50) | 18 (69.23) | ||
| Sex | 0.220 | 0.787 | ||
| Male | 19 (59.38) | 17 (65.38) | ||
| Female | 13 (40.62) | 9 (34.62) | ||
| BMI (kg/m2) | 26.42±1.05 | 25.84±1.17 | 1.988 | 0.052 |
| Operation duration (min) | 194.52±42.41 | 195.83±45.61 | 0.113 | 0.910 |
| Revival time (min) | 22.15±8.23 | 23.36±9.42 | 0.522 | 0.604 |
| Smoking status | 0.620 | 0.543 | ||
| Used to smoke | 23 (71.88) | 21 (80.77) | ||
| Never smoke | 9 (28.12) | 5 (19.23) | ||
| ASA classification | 1.115 | 0.429 | ||
| I | 18 (56.25) | 11 (42.31) | ||
| II | 14 (43.75) | 15 (57.69) | ||
| Degree of education | 0.130 | 0.778 | ||
| Junior secondary school and below | 10 (31.25) | 7 (26.92) | ||
| Junior high school or above | 22 (68.75) | 19 (73.08) | ||
| Preoperative heart rate (time/min) | 78.23±9.13 | 77.84±8.91 | 0.164 | 0.871 |
| Mean arterial pressure during operation (mmHg) | 88.62±15.22 | 86.28±16.57 | 0.560 | 0.578 |
| Blood loss during operation (ml) | 102.56±34.85 | 100.17±29.74 | 0.277 | 0.783 |
| Infusion volume during operation (ml) | 1,263.25±342.12 | 1,186.64±320.73 | 0.872 | 0.387 |
Figure 1.Comparison of pulmonary function between two groups. (A) There was no significant difference in A-aDO2 level at T1, T2, T3 and T5 between sevoflurane and propofol groups (P>0.05). The A-aDO2 level at T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher A-aDO2 level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower A-aDO2 level at T5 than that at T4, and the difference was statistically significant (P<0.05). (B) There was no significant difference in RI level at T1, T2 and T5 between sevoflurane and propofol groups (P>0.05). The RI level at T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher RI level at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher RI level at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower RI level at T4, T5 than that at T3. Both sevoflurane and propofol groups had significantly lower RI level at T5 than that at T4, and the difference was statistically significant (P<0.05). (C) There was no significant difference in Qs/Qt at T1, T5 between sevoflurane and propofol group (P>0.05). The Qs/Qt at T2, T3 and T4 in sevoflurane group was significantly higher than that in propofol group, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher Qs/Qt at T2, T3, T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly higher Qs/Qt at T3 and T4 than that at T2, and both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T2. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T4 and T5 than that at T3. Both sevoflurane and propofol groups had significantly lower Qs/Qt at T5 than that at T4, and the difference was statistically significant (P<0.05). *P<0.05 compared with T1; #P<0.05 compared with T2; &P<0.05 compared with T3; △P<0.05 compared with T4; @P<0.05. A-aDO2, alveolar-arterial oxygen difference; RI, respiratory index; Qs/Qt, intrapulmonary shunt ratio.
Comparison of pulmonary function between two groups.
| Index | No. | T1 | T2 | T3 | T4 | T5 | F | P-value |
|---|---|---|---|---|---|---|---|---|
| A-aDO2 (mmHg) | ||||||||
| Sevoflurane | 32 | 23.56±1.72 | 213.54±28.46[ | 426.52±43.26[ | 244.73±33.25[ | 26.49±1.93[ | 1201.00 | <0.05 |
| Propofol | 26 | 23.41±1.47 | 207.16±25.31[ | 413.64±44.82[ | 219.67±31.48[ | 25.64±1.75[ | 938.10 | <0.05 |
| t | 0.352 | 0.892 | 1.110 | 2.923 | 1.738 | |||
| P-value | 0.726 | 0.376 | 0.272 | 0.005 | 0.088 | |||
| RI | ||||||||
| Sevoflurane | 32 | 0.26±0.02 | 0.52±0.08[ | 2.06±0.33[ | 0.82±0.13[ | 0.33±0.06[ | 639.90 | <0.05 |
| Propofol | 26 | 0.25±0.03 | 0.49±0.09[ | 1.82±0.24[ | 0.71±0.12[ | 0.34±0.07[ | 616.10 | <0.05 |
| t | 1.517 | 1.343 | 3.100 | 3.316 | 0.586 | |||
| P-value | 0.135 | 0.185 | 0.003 | 0.002 | 0.560 | |||
| Qs/Qt (%) | ||||||||
| Sevoflurane | 32 | 8.92±1.24 | 12.68±1.72[ | 24.56±3.17[ | 15.28±1.93[ | 9.43±1.92[ | 294.10 | <0.05 |
| Propofol | 26 | 8.67±1.52 | 10.93±1.74[ | 20.73±2.73[ | 13.15±1.62[ | 9.34±1.75[ | 167.50 | <0.05 |
| t | 0.690 | 3.834 | 4.865 | 4.486 | 0.185 | |||
| P-value | 0.493 | <0.05 | <0.05 | <0.05 | 0.854 | |||
P<0.05 compared with T1
P<0.05 compared with T2
P<0.05 compared with T3
P<0.05 compared with T4. A-aDO2, alveolar-arterial oxygen difference; RI, respiratory index; Qs/Qt, intrapulmonary shunt ratio
Figure 2.Comparison of MMP-9 between the two groups. There was no significant difference in MMP-9 level at T1 and T5 between sevoflurane and propofol groups (P>0.05). The MMP-9 level at T4 in the sevoflurane group was significantly higher than that in the propofol group, the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly higher MMP-9 level at T4 and T5 than that at T1. Both sevoflurane and propofol groups had significantly lower MMP-9 level at T5 than that at T4, and the difference is statistically significant (P<0.05). *P<0.05 compared with T1; #P<0.05 compared with T4; @P<0.05. MMP-9; matrix metalloproteinase-9.
Comparison of MMP-9 between the two groups.
| Index | No. | T1 | T4 | T5 | F | P-value |
|---|---|---|---|---|---|---|
| MMP-9 (ng/ml) | ||||||
| Sevoflurane | 32 | 100.26±14.85 | 186.72±19.42[ | 114.56±15.61[ | 245.100 | <0.05 |
| Propofol | 26 | 102.14±13.76 | 167.25±14.73[ | 109.68±15.26[ | 154.800 | <0.05 |
| t | 0.495 | 4.218 | 1.196 | |||
| P-value | 0.622 | <0.05 | 0.237 | |||
P<0.05 compared with T1
P<0.05 compared with T4. MMP-9, matrix metalloproteinase-9
Figure 3.Comparison of cognitive function between the two groups. There was no significant difference in MMSE score between sevoflurane group and propofol group 1 day before surgery (P>0.05). The MMSE score in sevoflurane group was significantly lower than that in propofol group 1 and 10 days after surgery, and the difference was statistically significant (P<0.05). Both sevoflurane and propofol groups had significantly lower MMSE score of 1 and 10 days after surgery than that of 1 day before surgery. Both sevoflurane and propofol groups had significantly higher MMSE score of 10 d after surgery than that of 1 day after surgery, and the difference was statistically significant (P<0.05). *P<0.05 compared with 1 day before surgery; #P<0.05 compared with 1 day after surgery; @P<0.05; MMSE, Mini-Mental State Examination.
Comparison of cognitive function between the two groups.
| Index | No. | 1 day before surgery | 1 day after surgery | 10 day after surgery | F | P-value |
|---|---|---|---|---|---|---|
| MMSE score | ||||||
| Sevoflurane | 32 | 28.86±1.13 | 21.84±1.02[ | 27.21±1.03[ | 311.100 | <0.05 |
| Propofol | 26 | 29.23±1.05 | 24.86±1.08[ | 28.65±1.18[ | 147.700 | <0.05 |
| t | 1.290 | 10.860 | 4.889 | |||
| P-value | 0.202 | <0.05 | <0.05 | |||
P<0.05 compared with 1 day before surgery
P<0.05 compared with 1 day after surgery. MMSE, Μini-Μental State Examination